Table 2.
Univariate analysis of prognostic factors of each endpoint
| Factor | 2y-OS | 2y-LC | 2y-PFS | ||||
|---|---|---|---|---|---|---|---|
| % | P | % | P | % | P | ||
| Age (years) | < 66 (n = 57) | 56.6 | 0.21 | 50.8 | 0.04 | 16.2 | 0.150 |
| ≥ 66 (n = 56) | 71.3 | 69.2 | 22.5 | ||||
| Gender | Male (n = 45) | 55.1 | 0.11 | 59.1 | 0.42 | 21.1 | 0.97 |
| Female (n = 68) | 68.2 | 60.3 | 17.8 | ||||
| Performance status | 0 (n = 68) | 69.2 | 0.49 | 61.6 | 0.97 | 19.1 | 0.93 |
| 1–2 (n = 45) | 54.5 | 56.7 | 19.9 | ||||
| Primary site | Colorectum | 73.5 | 0.49 | 64.1 | 0.79 | 21.9 | 0.96 |
| Uterine cervix | 88.4 | 60.7 | 25.8 | ||||
| Endometrium | 54.4 | 59.3 | 23.3 | ||||
| Pathological type | Adenocarcinoma | 66.1 | 0.86 | 59.7 | 0.37 | 19.4 | 0.76 |
| Squamous cell carcinoma | 67.2 | 60.4 | 23.5 | ||||
| Initial T-category | T1–2 (n = 64) | 68.7 | 0.07 | 64.2 | 0.61 | 22.9 | 0.69 |
| T3–4 (n = 49) | 56.0 | 54.7 | 16.2 | ||||
| Initial N-category | N negative (n = 49) | 66.6 | 0.09 | 64.2 | 0.72 | 23.8 | 0.61 |
| N positive (n = 64) | 60.2 | 56.1 | 16.6 | ||||
| Duration from initial diagnosis (months) | < 24.1 (n = 57) | 60.9 | 0.94 | 63.8 | 0.43 | 20.7 | 0.59 |
| ≥ 24.1 (n = 56) | 63.9 | 54.9 | 18.0 | ||||
| DFI (months) | < 8.5 (n = 57) | 53.4 | 0.04 | 52.4 | 0.30 | 13.5 | 0.01 |
| ≥ 8.5 (n = 56) | 72.5 | 66.0 | 24.9 | ||||
| Radiation therapy method | 3DCRT (n = 47) | 56.1 | 0.49 | 50.9 | 0.01 | 26.0 | 0.82 |
| IMRT&SBRT (n = 66) | 67.9 | 64.9 | 14.5 | ||||
| Extra-regional LN for primary site | no (n = 65) | 65.5 | 0.07 | 60.6 | 0.92 | 21.9 | 0.45 |
| yes (n = 48) | 59.7 | 57.7 | 15.3 | ||||
| Number of LN | 1 (n = 61) | 73.3 | 0.01 | 70.4 | 0.01 | 25.1 | 0.08 |
| 2–5 (n = 52) | 51.3 | 47.8 | 12.9 | ||||
| LN size (cm) | < 2 (n = 62) | 71.6 | 0.17 | 66.0 | 0.06 | 18.1 | 0.68 |
| ≥ 2 (n = 51) | 52.0 | 52.4 | 20.7 | ||||
| Prophylactic nodal irradiation | no (n = 69) | 63.7 | 0.69 | 63.3 | 0.41 | 15.8 | 0.80 |
| yes (n = 44) | 61.4 | 54.9 | 28.2 | ||||
| Concurrent chemotherapy | no (n = 80) | 63.5 | 0.92 | 58.8 | 0.69 | 11.0 | 0.20 |
| yes (n = 33) | 59.5 | 60.8 | 36.1 | ||||
| EQD2 (Gy) | < 60 (n = 58) | 52.7 | 0.08 | 45.2 | < 0.001 | 21.1 | 0.87 |
| ≥ 60 (n = 55) | 74.8 | 74.9 | 17.5 | ||||
n number of patients, OS overall survival rate, LC local control rate, PFS progression-free survival rate, DFI disease-free interval, 3DCRT 3-dimentional conformal radiation therapy, IMRT intensity-modulated radiation therapy, SBRT Stereotactic Body Radiation Therapy, LN lymph node, EQD2 equivalent dose in 2 Gy fraction